Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337547 | 0.77 | CCR2 (0.36) | CNR1CNR2CCR2NAAA | |
| SCHEMBL1929440 | 0.77 | TACR3 (0.36) | — | |
| SCHEMBL1927824 | 0.77 | BCHE (0.36) | ALOX5PTGESPPARG | |
| SCHEMBL5442717 | 0.76 | KDM4E (0.34) | — | |
| SCHEMBL1928938 | 0.74 | HDAC4 (0.40) | — | |
| SCHEMBL5435448 | 0.67 | CNR1 (0.37) | CNR1CNR2CCR2NAAACCR1 | |
| SCHEMBL1928432 | 0.63 | MEN1 (0.36) | — | |
| SCHEMBL1927415 | 0.60 | CNR2 (0.35) | CNR2 | |
| SCHEMBL7063076 | 0.59 | GRIK1 (0.42) | — | |
| SCHEMBL28004557 | 0.58 | NAAA (0.55) | PPARGNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, SDHA | CNR1 432/4885CNR2 350/4885CCR2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.